Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Altamira Therapeutics Ltd (NQ: CYTO )

0.4375 UNCHANGED
Streaming Delayed Price Updated: 3:58 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Altamira Therapeutics Ltd

< Previous 1 2 3 4 5 6 7 8 9 Next >
Altamira Therapeutics Issues Shareholder Letter
Highlights Company's progress to becoming a pure-play RNA business and tech strategy and penetrate the multi-billion TAM HAMILTON, BERMUDA / ACCESSWIRE / May 18, 2022 / Altamira Therapeutics Ltd.... 
From Altamira Therapeutics
Via AccessWire
Altamira Receives Regulatory Approval from the Ministry of Health to Expand COVAMID Trial for Bentrio in Acute COVID-19 into North Macedonia
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
From Altamira Therapeutics
Via AccessWire
Exposures COVID-19
Altamira Reaches COVAMID Trial Enrollment Midpoint for Bentrio in Acute COVID-19
HAMILTON, BERMUDA / ACCESSWIRE / April 19, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced... 
From Altamira Therapeutics
Via AccessWire
Exposures COVID-19
Altamira Therapeutics Provides Business Update and Reports Second Half and Full Year 2021 Financial Results
- Management will host an investor conference call today, Tuesday, at 8 a.m. Eastern. - Company pivots towards RNA therapeutics and its OligoPhore™ / SemaPhore™ platform for extrahepatic RNA deliver -... 
From Altamira Therapeutics
Via AccessWire
Earnings Scheduled For March 10, 2022
Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares... 
Via Benzinga
Why Altamira Therapeutics Stock Is Soaring
Altamira Therapeutics Ltd (NASDAQ: CYTO) shares are trading higher Monday after the company announced a peer-reviewed publication on positive in vitro data with its Bentrio... 
Via Benzinga
Altamira Therapeutics Announces Peer-Reviewed Publication on Positive in vitro Data with its Bentrio(TM) Drug-Free Nasal Spray Against SARS-CoV-2 Delta Variant
Study Confirms in vitro Efficacy / Safety of Bentrio(TM) for Delta Variant - Prophylactic treatment of human nasal mucosa with Bentrio™ was reported to significantly reduce the viral titer vs. controls... 
From Altamira Therapeutics
Via AccessWire
Altamira Therapeutics FY 2021 Earnings Conference Call On April 12, 2022 At 08:00 AM ET
Altamira Therapeutics (NASDAQ:CYTO) will host a conference call at 08:00 AM ET on April 12, 2022, to discuss FY 2021 earnings results. How to Attend Altamira Therapeutics (CYTO) Conference Call Follow... 
Via Benzinga
Altamira Therapeutics Sets Full Year 2021 Earnings Call for Tuesday, April 12, 2022, 8:00 a.m. ET
HAMILTON, BERMUDA / ACCESSWIRE / April 4, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced it... 
From Altamira Therapeutics
Via AccessWire
Topics Earnings
Exposures Financial
Altamira Therapeutics Completes Patient Enrollment in House Dust Mite Allergy Trial with Bentrio
HAMILTON, BERMUDA / ACCESSWIRE / March 15, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced... 
From Altamira Therapeutics
Via AccessWire
95 Biggest Movers From Friday
Gainers Marygold Companies (NYSE: MGLD) shares surged 89.4% to close at $4.11 on Friday after dropping 21% on Thursday. TeraWulf Inc. (NASDAQ: WULF) gained 49.3% to close at $9.... 
Via Benzinga
Mid-Afternoon Market Update: Nasdaq Falls 150 Points; Orphazyme Shares Plunge
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq dropping 150 points on Friday. The Dow traded up 0.07% to 33,198.82 while the NASDAQ fell 1.18% to 12,... 
Via Benzinga
Why Are Altamira Therapeutics Shares Gaining Today?
Altamira Therapeutics Ltd (NASDAQ: CYTO) shares are surging after announcing preclinical efficacy data from testing its Bentrio nasal spray against the omicron... 
Via Benzinga
Mid-Day Market Update: Gold Down 1%; Clearside Biomedical Shares Jump
U.S. stocks traded mixed midway through trading, with the Nasdaq dropping around 100 points on Friday. The Dow traded up 0.49% to 33,336.14 while the NASDAQ fell 0.73% to 13,032.... 
Via Benzinga
Altamira Therapeutics Reports Positive In Vitro Efficacy Data for Bentrio Nasal Spray in Protecting Against Sars-CoV-2 Omicron Variant
HAMILTON, BERMUDA / ACCESSWIRE / March 11, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced... 
From Altamira Therapeutics
Via AccessWire
50 Stocks Moving In Friday's Mid-Day Session
Gainers Marygold Companies (NYSE: MGLD) jumped 189.4% to $6.28 after dropping 21% on Thursday. Altamira Therapeutics Ltd. (NASDAQ: CYTO) shares rose 63.5% to $1.13.... 
Via Benzinga
30 Stocks Moving in Friday's Pre-Market Session
Gainers Excellon Resources Inc. (NYSE: EXN) rose 133.7% to $2.29 in pre-market trading after jumping around 13% on Thursday. Marygold Companies (NYSE: MGLD) rose 107.4% to... 
Via Benzinga
Altamira Therapeutics Receives Approval to Commence Clinical Trial Evaluating Bentrio in the Treatment of COVID-19
HAMILTON, BERMUDA / ACCESSWIRE / March 9, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced... 
From Altamira Therapeutics
Via AccessWire
Exposures COVID-19
88 Biggest Movers From Yesterday
Gainers Hycroft Mining Holding Corporation (NASDAQ: HYMC) climbed 203.3% to settle at $1.00 on Tuesday. Hycroft recently reported preliminary FY21 operating results. Kala... 
Via Benzinga
Altamira, Nuance Pharma Ink Licensing Pact For Bentrio In China, Additional Asian Markets
Altamira Therapeutics Ltd (NASDAQ: CYTO) has entered into an exclusive licensing and distribution agreement with Nuance Pharma Ltd in the Chinese Mainland... 
Via Benzinga
Altamira Therapeutics and Nuance Pharma Enter Into Exclusive Licensing and Distribution Agreement for Bentrio in China and Additional Asian Markets
- Nuance Pharma to develop and commercialize Bentrio™ nasal spray in Chinese Mainland, Hong Kong, Macau and South Korea - Altamira to receive up to $23.5 million in upfront and milestone payments... 
From Altamira Therapeutics
Via AccessWire
Altamira Therapeutics Completes Final Patient Enrollment in Phase 2 'TRAVERS' Clinical Trial of AM-125 for the Treatment of Acute Vertigo
- 75 patients randomized in Part B of study to receive either intranasal betahistine or placebo - Top-line results from the trial expected to be announced in Q2-2022 HAMILTON, BERMUDA / ACCESSWIRE /... 
From Altamira Therapeutics
Via AccessWire
Altamira Therapeutics and Wellesta Expand Bentrio Marketing and Distribution Agreement to Include Two Additional Markets
HAMILTON, BERMUDA / ACCESSWIRE / February 9, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced... 
From Altamira Therapeutics
Via AccessWire
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 95 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: The largest company by market cap to set a new 52-... 
Via Benzinga
Altamira Therapeutics and Avernus Pharma Collaborate for Marketing and Distribution of Bentrio in Gulf Countries
HAMILTON, BERMUDA / ACCESSWIRE / February 7, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced today... 
From Altamira Therapeutics
Via AccessWire
Altamira Therapeutics Establishes OTC Consumer Health Business Unit
- Dedicated unit to support Altamira's activities in consumer health products - OTC Consumer Health to be led by experienced marketing strategist, Jean Lachance HAMILTON, BERMUDA / ACCESSWIRE /... 
From Altamira Therapeutics
Via AccessWire
Altamira's Bentrio Nasal Spray Approved In Malaysia
The Medical Device Authority of Malaysia has approved Altamira Therapeutics Ltd's (NASDAQ: CYTO) Bentrio. "We are very pleased with the swift 'go... 
Via Benzinga
Altamira Therapeutics Announces Approval of Bentrio Nasal Spray in Malaysia
HAMILTON, BERMUDA / ACCESSWIRE / January 21, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection... 
From Altamira Therapeutics
Via AccessWire
Altamira Therapeutics Provides Update on RNA Therapeutics Program
- Covadonga Pañeda, Ph.D., to join leadership team as Chief Development Officer for RNA therapeutics - Receipt of NIH grant to help advance siRNA delivery platform for use in extrahepatic inflammatory... 
From Altamira Therapeutics
Via AccessWire
Altamira Therapeutics to Participate in the H.C. Wainwright BioConnect Virtual Conference
HAMILTON, BERMUDA / ACCESSWIRE / January 5, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection... 
From Altamira Therapeutics
Via AccessWire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.